Research output per year
Research output per year
Personal profile
Interests
Dr. Greene completed her PhD within the School of Pharmacy at Queen’s University Belfast, which focused on the therapeutic evaluation of a novel immunomodulatory nanoparticle in models of Acute Respiratory Distress Syndrome. Within her present role as a postdoctoral researcher, Dr. Greene has continued to apply her expertise in nanomedicine, particularly in the field of oncology. She is currently engaged in a US-Ireland R&D Partnership Programme that aims to develop more effective therapies for pancreatic cancer, by combining nanomedicines with agents that can overcome the drug delivery barriers posed by the tumour microenvironment.
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Michelle Greene is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Network
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Enhanced target-specific delivery of docetaxel-loaded nanoparticles using engineered T cell receptors
McDaid, W. J., Lissin, N., Pollheimer, E., Greene, M., Leach, A., Smyth, P., Bossi, G., Longley, D., Cole, D. K. & Scott, C. J., 20 Aug 2021, (Early online date) In: Nanoscale. 13, 35, p. 15010-15020Research output: Contribution to journal › Article › peer-review
Open AccessFile42 Downloads (Pure) -
Nanomedicine in Pancreatic Cancer: Current Status and Future Opportunities for Overcoming Therapy Resistance
Greene, M. K., Johnston, M. C. & Scott, C. J., 07 Dec 2021, (Early online date) In: Cancers. 13, 24, 26 p., 6175.Research output: Contribution to journal › Review article › peer-review
Open AccessFile102 Downloads (Pure) -
Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature
Leach, A., Smyth, P., Ferguson, L., Steven, J., Greene, M. K., Branco, C. M., McCann, A. P., Porter, A., Barelle, C. J. & Scott, C. J., 21 Jul 2020, In: Nanoscale. 12, 27, p. 14751-14763 13 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile5 Citations (Scopus)47 Downloads (Pure) -
Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
Greene, M. K., Chen, T., Robinson, E., Straubinger, N. L., Minx, C., Chan, D. K. W., Wang, J., Burrows, J. F., Van Schaeybroeck, S., Baker, J. R., Caddick, S., Longley, D. B., Mager, D. E., Straubinger, R. M., Chudasama, V. & Scott, C. J., 11 Sep 2020, In: British Journal of Cancer.Research output: Contribution to journal › Article › peer-review
Open AccessFile1 Citation (Scopus)128 Downloads (Pure) -
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models
Johnston, M., Nicoll, J., Redmond, K., Smyth, P., Greene, M., McDaid, W., Crawford, N., Stott, K., Fox, J., Longley, D. & Scott, C., 10 Aug 2020, In: Journal of Controlled Release. 324, p. 610-619 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile6 Citations (Scopus)141 Downloads (Pure)